Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Review
DOI: 10.54448/ijn23228
Submitted: 06-20-2023
Published: 06-20-2023

Major aspects of cannabidiol in the interaction with microRNAs and exosomes in the modulation of inflammatory and immunological processes in athletes: a systematic review

Medical Clinic. Higienópolis Avenue, 15, 114-O, Higienópolis, São Paulo, Brazil
Apothek Institute Teaching and Research Center, Porto Alegre, Rio Grande do Sul, Brazil
Vanessa Cremasco Clinic. Pedroso Alvarenga Street, 584 - Itaim Bibi, São Paulo, Brazil
Medical Clinic. Rua Joao Borba 131. Moóca, São Paulo, Brazil
Medical Clinic. Edifício New York Square, C-136 Avenue, 797, setor sul, Goiânia, Goiás, Brazil
Sports nutrition Cannabidiol Cannabis microRNAs Exosomes Metabolism Inflammatory processes Immunological processes Athletes

Abstract

Introduction: The correct interaction between elements of the endocannabinoid system plays an important role in the development of the central nervous system. Clinical and preclinical studies suggest that cannabidiol (CBD) may be useful for athletes due to its anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties and its influence on the sleep-wake cycle. In addition, a series of implications for epigenetic processes have also been proven, through changes in the expression of microRNAs responsible for modulating the immune and inflammatory systems. Objective: It was to develop a systematic review study to highlight the main aspects of cannabidiol in the interaction with microRNAs and exosomes in the modulation of inflammatory and immunological processes in athletes. Methods: The systematic review rules of the PRISMA Platform were followed. The research was carried out from February to April 2023 in Scopus, PubMed, Science Direct, Scielo, and Google Scholar databases. The quality of the studies was based on the GRADE instrument and the risk of bias was analyzed according to the Cochrane instrument. Results and Conclusion: A total of 228 articles were found, and 84 articles were evaluated in full and 60 were included and developed in this systematic review study. Considering the Cochrane tool for risk of bias, the overall assessment resulted in 20 studies with a high risk of bias and 90 studies that did not meet GRADE. CBD has been reported to exert a range of physiological, biochemical, and psychological effects with the potential to benefit human health. For example, there is preliminary supporting evidence for the anti-inflammatory, neuroprotective, analgesic, and anxiolytic actions of CBD and the possibility that it may protect against gastrointestinal damage associated with inflammation and promote the healing of traumatic skeletal injuries. The combination of Δ9-THC and CBD can alter the activity of microRNAs responsible for increasing the biosynthesis of inflammatory mediators, leading to a reduction in the inflammatory profile. However, it is important to recognize that these findings are very preliminary, sometimes inconsistent, and largely derived from preclinical studies. These studies are limited in their generalizability to athletes and often administer high doses of CBD. The central observation is that there is a lack of studies that directly investigate CBD and sports performance.

Metrics

Metrics Loading ...

References

  1. Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiol Psychiatr Sci. 2018, Aug;27(4):327-335. doi: 10.1017/S2045796018000239.
  2. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Front Immunol. 2018, Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009.
  3. Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Pina SD, Tambaro S, Memo M, Mastinu A. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life Sci. 2019, May 1;224:120-127. doi: 10.1016/j.lfs.2019.03.053.
  4. Elms L, shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment of PostTraumatic Stress Disorder: A Case Series. J Altern Complement Med. Apr; 2019, 25(4):392-397. doi: 10.1089/acm.2018.0437.
  5. Gruden G, Barutta F, Kunos G, Pacher P. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol. 2016, Apr;173(7):1116-27. doi: 10.1111/bph.13226.
  6. Kaur R, Ambwani SR, Singh S. Endocannabinoid System: A Multi-Facet Therapeutic Target. Curr Clin Pharmacol. 2016, 11(2):110-7.
  7. Gamelin FX, Cuvelier G, Mendes A, Aucouturier J, Berthoin S, Di Marzo V, Heyman E. Cannabidiol in sport: Ergogenic or else? Pharmacol Res. 2020 Jun;156:104764. doi: 10.1016/j.phrs.2020.104764.
  8. Rogobete A.F., Sandesc D., Bedreag O.H., Papurica M., Popovici S.E., Bratu T., Popoiu C.M., Nitu R., Dragomir T., AAbed H.I.M., et al. MicroRNA Expression is Associated with Sepsis Disorders in Critically Ill Polytrauma Patients. Cells. 2018;7:271. doi: 10.3390/cells7120271.
  9. Dinu AR, Rogobete AF, Bratu T, Popovici SE, Bedreag OH, Papurica M, Bratu LM, Sandesc D. Cannabis Sativa Revisited-Crosstalk between microRNA Expression, Inflammation, Oxidative Stress, and Endocannabinoid Response System in Critically Ill Patients with Sepsis. Cells. 2020 Jan 28;9(2):307. doi: 10.3390/cells9020307.
  10. Daniel Lafreniere J, Lehmann C. Parameters of the endocannabinoid system as novel biomarkers in sepsis and septic shock. Metabolites. 2017;7:55. doi: 10.3390/metabo7040055.
  11. Meza A, Lehmann C. Betacaryophyllene—A phytocannabinoid as potential therapeutic modality for human sepsis? Med. Hypotheses. 2018;110:68–70. doi: 10.1016/j.mehy.2017.10.025.
  12. Chiarlone A, Börner C, Martín-Gómez L, Jiménez-González A, García-Concejo A, García-Bermejo ML, Lorente M, Blázquez C, García-Taboada E, de Haro A, et al. MicroRNA let-7d is a target of cannabinoid CB1 receptor and controls cannabinoid signaling. Neuropharmacology. 2016;108:345–352. doi: 10.1016/j.neuropharm.2016.05.007.
  13. Id AJ, Gao F, Coppola G, Vogel Z, Kozela E. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia—Effect of cannabinoids. PLoS ONE 2019, 14, e0212039.
  14. Dumache R, Ciocan V, Muresan C, Rogobete AF, Enache A. Circulating microRNAs as promising biomarkers in forensic body fluids identification. Clin. Lab. 2015, 61, 1129–1135.
  15. Dumache R, Rogobete AF, Bedreag OH, Sarandan M, Cradigati AC, Papurica M, Dumbuleu CM, Nartita R, Sandesc D. Use of miRNAs as Biomarkers in Sepsis. Anal. Cell. Pathol. 2015, 2015, 186716.
  16. Cd HS, Cells SCD, Wu Q, Zhan J, Li Y, Wang X, Xu L, Yu J, Pu S, Zhou Z. Differentiation-Associated MicroRNA Alterations in Mouse. Stem cells International 2016, 2016.
  17. Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: Feedback control of inflammation. J. Immunol. 2010, 184, 21–25.
  18. Ganan-Gomez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, BoyanoAdanez MDC, Garcia-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-kappaB activation and enhances erythroid differentiation arrest. PLoS ONE 2014, 9, e93404.
  19. Ho J, Chan H,Wong SH, Wang MHT, Yu J, Xiao Z, Liu X, Choi G, Leung CCH, Wong WT et al. The involvement of regulatory non-coding RNAs in sepsis: A systematic review. Crit. Care 2016, 20, 1–12.
  20. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy. Behav. 2017, 70, 313–318.
  21. O’Neill LAJ, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 2007, 7, 353–364.
  22. Liang H, Yan X, Pan Y, Wang Y, Wang N, Li L, Liu Y, Chen X. MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol. Cancer 2015, 14, 58.
  23. Qi J, Qiao Y, Wang P, Li S, Zhao W, Gao C. microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-kappaB1 in murine macrophages. FEBS Lett. 2012, 586, 1201–1207.
  24. Meng QT, Chen R, Chen C, Su K, Li W, Tang LH, Liu HM, Xue R, Sun Q, Leng Y et al. Transcription factors Nrf2 and NF-κB contribute to inflammation and apoptosis induced by intestinal ischemia-reperfusion in mice. Int. J. Mol. Med. 2017, 40, 1731–1740.
  25. Xiao B, Liu Z, Li BS, Tang B, Li W, Guo G, Shi Y, Wang F, Wu Y, Tong WD, et al. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. J. Infect. Dis. 2009, 200, 916–925.
  26. Wu M, Gu JT, Yi BIN, Tang ZZHI, Tao GU. MicroRNA-23b regulates the expression of inflammatory factors in vascular endothelial cells during sepsis. Exp. Ther. Med. 2015, 9, 1125–1132.
  27. Juknat A, Kozela E, Gao F, Kaushansky N, Coppola G, Vogel Z. Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells. J. Neuroinflammation 2016, 13, 1–19.
  28. Yang X, Bam M, Nagarkatti PS, Nagarkatti M. RNA-seq Analysis of δ9Tetrahydrocannabinol-treated T Cells Reveals Altered Gene Expression Profiles That Regulate Immune Response and Cell Proliferation. J. Biol. Chem. 2016, 291, 15460–15472.
  29. Ganan-Gomez I, Wei Y, Yang H, Pierce S, Bueso-Ramos C, Calin G, BoyanoAdanez MDC, Garcia-Manero G. Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-kappaB activation and enhances erythroid differentiation arrest. PLoS ONE 2014, 9, e93404.
  30. Ho J, Chan H, Wong SH, Wang MHT, Yu J, Xiao Z, Liu X, Choi G, Leung CCH, Wong WT et al. The involvement of regulatory non-coding RNAs in sepsis: A systematic review. Crit. Care 2016, 20, 1–12.
  31. Li Y, Dalli J, Chiang N, Baron RM, Quintana C, Serhan CN. Article Plasticity of Leukocytic Exudates in Resolving Acute Inflammation Is Regulated by MicroRNA and Proresolving Mediators. Immunity 2013, 39, 885–898.
  32. Ma X, Buscaglia LEB, Barker JR, Li Y. MicroRNAs in NF-kB signaling. J. Mol. Cell Biol. 2011, 3, 159–166.
  33. Rao R, Nagarkatti PS, Nagarkatti M. D9 Tetrahydrocannabinol attenuates Staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells Tables of Links. Br. J. Pharmacol. 2015, 172, 1792–1806.
  34. Chiarlone A, Börner C, Martín-Gómez L, Jiménez-González, A.; García-Concejo, A.; García-Bermejo, M.L, Lorente, M.; Blázquez, C.; García-Taboada, E.; de Haro, A.; et al. MicroRNA let-7d is a target of cannabinoid CB1 receptor and controls cannabinoid signaling. Neuropharmacology 2016, 108, 345–352.
  35. Sido JM, Jackson AR, Nagarkatti PS, Nagarkatti, M. Marijuana-derived D-9tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation. J. Mol. Med. 2016, 94, 1039– 1051.
  36. Al-Ghezi ZZ, Miranda K, Nagarkatti M, Nagarkatti PS. Combination of Cannabinoids, D9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways. Front. Immunol. 2019, 10, 1–17.
  37. Di Palo A, Siniscalchi C, Crescente G, De Leo I, Fiorentino A, Pacifico S, Russo A, Potenza N. Effect of Cannabidiolic Acid, N-Trans-Caffeoyltyramine and Cannabisin B from Hemp Seeds on microRNA Expression in Human Neural Cells. Curr Issues Mol Biol. 2022 Oct 21;44(10):5106-5116. doi: 10.3390/cimb44100347.
  38. Juknat A, Gao F, Coppola G, Vogel Z, Kozela E. miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia-Effect of cannabinoids. PLoS One. 2019 Feb 11;14(2):e0212039. doi: 10.1371/journal.pone.0212039.
  39. Stone WJ, Tolusso DV, Pancheco G, Brgoch S, Nguyen VT. A Pilot Study on Cannabidiol (CBD) and Eccentric Exercise: Impact on Inflammation, Performance, and Pain. Int J Exerc Sci. 2023 Jan 1;16(2):109-117.
  40. Marques Azzini GO, Marques Azzini VO, Santos GS, Visoni S, Fusco MA, Beker NS, Mahmood A, Bizinotto Lana JV, Jeyaraman M, Nallakumarasamy A, Jeyaraman N, da Fonseca LF, Luz Arab MG, Vicente R, Rajendran RL, Gangadaran P, Ahn BC, Duarte Lana JFS. Cannabidiol for musculoskeletal regenerative medicine. Exp Biol Med (Maywood). 2023 May 9:15353702231162086. doi: 10.1177/15353702231162086.
  41. McCartney D, Benson MJ, Desbrow B, Irwin C, Suraev A, McGregor IS. Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Med Open. 2020 Jul 6;6(1):27. doi: 10.1186/s40798-020-00251-0.
  42. Clarkson P, Nosaka K, Braun B. Muscle function after exercise-induced muscledamage and rapid adaptation. Med Sci Sports Exerc. 1992;24(5):512–20.
  43. Fatouros I, Jamurtas A. Insights into the molecular etiology of exercise-induced inflammation: opportunities for optimizing performance. J InflammRes. 2016;9:175–86.
  44. Smith L. Acute inflammation: The underlying mechanism in delayed onsetmuscle soreness? Med Sci Sports Exerc. 1991;23(5):542–51.
  45. Booz G. Cannabidiol as an emergent therapeutic strategy for lessening theimpact of inflammation on oxidative stress. Free Radic Biol Med. 2011;51(5):1054–61.
  46. Klein M, de Quadros De Bortolli J, Guimarães F, Salum F, Cherubini K, deFigueiredo M. Effects of cannabidiol, a Cannabis sativa constituent, on oralwound healing process in rats: Clinical and histological evaluation.Phytother Res. 2018;32(11):2275–81.
  47. Mukhopadhyay P, Rajesh M, Horváth B, et al. Cannabidiol protects againsthepatic ischemia/reperfusion injury by attenuating inflammatory signalingand response, oxidative/nitrative stress, and cell death. Free Radic Biol Med.2011;50(10):1368–81.
  48. Ribeiro A, Ferraz-de-Paula V, Pinheiro M, et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in amurine model of acute lung injury: Role for the adenosine A2A receptor.Eur J Pharmacol. 2012;678(1):78–85.
  49. Wang Y, Mukhopadhyay P, Cao Z, et al. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation andneutrophil-mediated injury. Sci Rep. 2017;7(1):12064.
  50. Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R. CannabidiolArrests Onset of Autoimmune Diabetes in NOD Mice. Neuropharmacology.2008;54(1): 244–9.
  51. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavini S, & Gallily R.Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.Autoimmunity. 2006;39(2):143–51.
  52. Philpott H, O’Brien M, McDougall J. Attenuation of early phase inflammationby cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain.2017;158(12):2442.
  53. Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but noteffective in the treatment for Crohn’s disease: A randomized controlled trial.Dig Dis Sci. 2017;62(6):1615–20.
  54. Iannotti F, Pagano E, Moriello A, et al. Effects of non-euphoric plantcannabinoids on muscle quality and performance of dystrophic MDX mice.Br J Pharmacol. 2019;176(10):1568–84.
  55. Lachenmeier DW, Diel P. A Warning against the Negligent Use of Cannabidiol in Professional and Amateur Athletes. Sports (Basel). 2019 Dec 14;7(12):251. doi: 10.3390/sports7120251.
  56. Cochrane-Snyman KC, Cruz C, Morales J, Coles M. The Effects of Cannabidiol Oil on Noninvasive Measures of Muscle Damage in Men. Med Sci Sports Exerc. 2021 Jan 21. doi: 10.1249/MSS.0000000000002606.
  57. Zeiger JS, Silvers WS, Fleegler EM, Zeiger RS. Age related differences in cannabis use and subjective effects in a large population-based survey of adult athletes. J Cannabis Res. 2019 Jul 29;1(1):7. doi: 10.1186/s42238-019-0006-9.
  58. Kramer A, Sinclair J, Sharpe L, Sarris J. Chronic cannabis consumption and physical exercise performance in healthy adults: a systematic review. J Cannabis Res. 2020 Oct 7;2(1):34. doi: 10.1186/s42238-020-00037-x.
  59. Mareck U, Fusshöller G, Geyer H, Huestis MA, Scheiff AB, Thevis M. Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use. Drug Test Anal. 2021 Mar;13(3):539-549. doi: 10.1002/dta.2959.
  60. Maurer GE, Mathews NM, Schleich KT, Slayman TG, Marcussen BL. Understanding Cannabis-Based Therapeutics in Sports Medicine. Sports Health. 2020 Nov/Dec;12(6):540-546. doi: 10.1177/1941738120956604.

How to Cite

Ichikawa, A. I. T., Conter, F. da S., Bubna, P., Ishikawa, V. N., & Gontijo, G. M. (2023). Major aspects of cannabidiol in the interaction with microRNAs and exosomes in the modulation of inflammatory and immunological processes in athletes: a systematic review. International Journal of Nutrology, 16(2). https://doi.org/10.54448/ijn23228